An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196

Trial Profile

An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Madrigal Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 11 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 20 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top